BA
KBIO

BlackRock Advisors’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

BlackRock Advisors’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,047
Closed -$23K – 3805
2014
Q1 		$23K Buy
1,047
+202
+24% +$5.85K ﹤0.01% 3394
2013
Q4 		$30K Buy
845
+140
+20% +$4.69K ﹤0.01% 3323
2013
Q3 		$25K Sell
705
-2,023
-74% -$92.1K ﹤0.01% 3286
2013
Q2 		$124K Buy
+2,728
New +$124K ﹤0.01% 2759

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock Advisors's KBIO Position: Q2 2014 in Review

BlackRock Advisors sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2014, closing a stake of 1,047 shares — an estimated $23K sold.

BlackRock Advisors first reported a position in KBIO in Q2 2013 and held it in 4 quarters. The position peaked at $124K in Q2 2013. 43 funds tracked by Wall St. Rank hold KBIO as of Q2 2014.

  • BlackRock Advisors reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2014 after selling out during the quarter.
  • BlackRock Advisors sold 1,047 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2014, an estimated $23K.
  • BlackRock Advisors first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 4 quarters.
  • BlackRock Advisors's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $124K in Q2 2013.
  • 43 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2014.

Based on BlackRock Advisors's 13F filing for Q2 2014, filed 6 Aug 2014.